0001104659-20-138756.txt : 20201222
0001104659-20-138756.hdr.sgml : 20201222
20201222203914
ACCESSION NUMBER: 0001104659-20-138756
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201222
FILED AS OF DATE: 20201222
DATE AS OF CHANGE: 20201222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Werner Milton H.
CENTRAL INDEX KEY: 0001827621
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39676
FILM NUMBER: 201409525
MAIL ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inhibikase Therapeutics, Inc.
CENTRAL INDEX KEY: 0001750149
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
BUSINESS PHONE: 678-392-3419
MAIL ADDRESS:
STREET 1: 3350 RIVERWOOD PARKWAY SE, SUITE 1900
CITY: ATLANTA
STATE: GA
ZIP: 30339
3
1
tm2034420d1_form3.xml
FORM 3
X0206
3
2020-12-22
0
0001750149
Inhibikase Therapeutics, Inc.
IKT
0001827621
Werner Milton H.
3350 RIVERWOOD PARKWAY SE, SUITE 1900
ATLANTA
GA
30339
1
1
1
0
President and CEO
Common Stock
5244938
D
Stock Option (right to buy)
0.38
2011-06-01
2021-06-01
Common Stock
43707
D
Stock Option (right to buy)
2.02
2023-06-01
Common Stock
21853
D
Stock Option (right to buy)
2.02
2025-03-01
Common Stock
21853
D
Stock Option (right to buy)
2.31
2025-11-01
Common Stock
21853
D
Stock Option (right to buy)
2.31
2026-11-01
Common Stock
21853
D
Stock Option (right to buy)
2.31
2027-11-01
Common Stock
21853
D
Stock Option (right to buy)
4.79
2028-11-01
Common Stock
21853
D
Stock Option (right to buy)
5.57
2029-11-01
Common Stock
21853
D
The number of shares has been adjusted to reflect a one-for-1.14396 reverse stock split of the Issuer's common stock effected on August 24, 2020 (the "Reverse Split").
The number of shares has been adjusted to reflect the Reverse Split and excludes fractional shares resulting from the Reverse Split, which shall be paid in cash upon exercise.
The exercise price has been adjusted to reflect the Reverse Split.
The option vested in twelve equal monthly installments beginning on June 1, 2013.
The option vested in twelve equal monthly installments beginning on March 1, 2015.
The option vested in twelve equal monthly installments beginning on November 1, 2015.
The option vested in twelve equal monthly installments beginning on November 1, 2016.
The option vested in twelve equal monthly installments beginning on November 1, 2017.
The option vested in twelve equal monthly installments beginning on November 1, 2018.
The option vested in twelve equal monthly installments beginning on November 1, 2019.
/s/ Milton H. Werner
2020-12-22